Sanofi has embraced digitization to streamline its manufacturing processes and automate documentation, with the aim of leveraging AI to cut down development and manufacturing timelines by 25%. The French pharmaceutical company is on a path to transforming into a “digital healthcare company” by 2025, utilizing digital technologies to drive innovation and efficiency throughout its research and development (R&D), manufacturing, and commercial activities.
Ariel Bismuth, Sanofi’s global digital head of manufacturing and supply, highlights the success of the company’s “digital lighthouse” plants in locations such as Geel, Waterford, Scoppito, Toronto, and Hangzhou. These sites serve as models of advanced digitalization and automation, showcasing the implementation of AI-driven solutions like predictive downtime optimization, adaptive process controls, in-silico bioprocess experimentation, and launch readiness simulation.
Sanofi’s AI-powered analytics platform, SimplY, has already demonstrated tangible results, such as an anticipated 8% increase in Dupixent drug substance output over the next three years at its Belgium site. Moreover, the development of a generative AI solution is expected to generate approximately 5,000 annual reports related to product quality and manufacturing science studies by the first half of 2026.
In addition to internal developments, Sanofi has collaborated with Aily Labs to utilize plAI technology for data collection across various operations, including development, manufacturing, logistics, and commercial activities. This software leverages AI to pinpoint areas for supply chain enhancements by analyzing data to identify root causes and offer actionable recommendations to over 3,000 users.
Sanofi’s strategic investment in IT infrastructure is integral to its digital transformation, aiming to become a leading biopharmaceutical company powered by AI at scale. By establishing dedicated digital teams and fostering collaboration with manufacturing and supply digital lighthouses, Sanofi aims to achieve right-first-time product launches, reduce timelines by 25%, and enhance network performance by 25%.
Key Takeaways:
– Sanofi’s digital initiatives, including AI-driven solutions, are central to optimizing manufacturing processes and enhancing efficiencies.
– The company’s investment in IT infrastructure and data operations underscores its commitment to becoming a digital drugmaker.
– Collaboration with technology partners like Aily Labs and internal development of AI solutions, such as SimplY, demonstrate Sanofi’s multifaceted approach to digital transformation.
– Establishing agile digital product teams and leveraging AI will be key strategies for Sanofi to drive innovation, reduce timelines, and improve network performance in manufacturing operations.
Tags: biotech, biopharma, bioprocess, automation
Read more on genengnews.com